XPACE-1007 is a preclinical therapeutic candidate from Xanadu Bio aimed at treating Non-Small Cell Lung Cancer (NSCLC). The asset leverages the company's proprietary poly(amine-co-ester) or PACE polymer nanoparticle platform.